[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355657-105":59,"doc-detail-355657-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","patient-derived-organotypic-tumor-spheroids-as-a-functional-platform-for-predicting-immunotherapeutic-responses-and-guiding-precision-treatment-for-hepatocellular-carcinoma-original-research","Patient-derived organotypic tumor spheroids as a functional platform for predicting immunotherapeutic responses and guiding precision treatment for hepatocellular carcinoma - Original research","","Hepatocellular carcinoma (HCC) continues to drive cancer mortality worldwide, yet immune checkpoint blockade shows limited and unpredictable benefit. An immune-competent patient-derived organotypic tumor spheroid (PDOTS) model was developed to preserve HCC heterogeneity and the immune microenvironment. Using patient tumor tissues, PDOTS enables rapid ex vivo assessment of targeted and immunotherapeutic responses, with fidelity, immune-dependent effects, and transcriptomic prediction of treatment sensitivity and resistance.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/patient-derived-organotypic-tumor-spheroids-as-a-functional-platform-for-predicting-immunotherapeutic-responses-and-guiding-precision-treatment-for-hepatocellular-carcinoma-original-research/355657/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/patient-derived-organotypic-tumor-spheroids-as-a-functional-platform-for-predicting-immunotherapeutic-responses-and-guiding-precision-treatment-for-hepatocellular-carcinoma-original-research/355657.png","ImageObject",300,407,{"name":92,"@type":93},"Bintang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the PDOTS model used for in this study?","Question",{"text":113,"@type":114},"The study uses patient-derived organotypic tumor spheroids (PDOTS) as an ex vivo functional platform to assess immunotherapeutic responses while preserving the tumor–immune microenvironment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were PDOTS prepared and maintained for immune response testing?",{"text":118,"@type":114},"Tumor tissues from 30 HCC patients were processed with a “Five-Point Clock” sampling method and cultured in a three-dimensional microfluidic chip supplemented with IL-2 and CD3/28 activator to maintain tumor-infiltrating lymphocyte activity.",{"name":120,"@type":111,"acceptedAnswer":121},"What predictive biomarker or model was derived from the PDOTS data?",{"text":122,"@type":114},"The work introduces the Organoid Killing Index (OKI) based on gene signatures from transcriptomic profiling, which correlated with and predicted clinical outcomes in an external cohort treated with atezolizumab plus bevacizumab.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355657,1790271326,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":31,"preview_page_count":19,"preview_urls":145},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Open access Original research  \n Patient-derived organotypic tumor  \nspheroids as a functional platform for predicting immunotherapeutic responses and guiding precision treatment for hepatocellular carcinoma  \nFei Song  ,1,2 Yi-Jun Lu,1 Hai-Xiang Sun,3 Jian-Wen Cheng,1 Wen-Zhen Li,4 Zhenhao Liu,4 Rui-Zhe Li,1 Peng-Xiang Wang,1 Wen-Jing Zheng  ,1  \nYu-Chen Zhong,1 Yang Xu,1 Jie Xu,2 Yu Wang,2 Su-Yan Bai,2 Lu Xie  ,4  \nKwan Man  ,5 Jia Fan  ,1,6 Jian Zhou  ,1,6 Zhong Chen,2 Xin-Rong Yang  1  \nTo cite: Song F, Lu Y-J, Sun H-X, et al. Patient-derived organotypic tumor spheroidsas a functional platform for predicting immunotherapeutic responses and guiding precision treatment for hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer 2026;14:e014555 . doi:10 . 1136/ jitc-2025-014555  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-014555](jitc-2025-014555)) .  \nFS, Y-JL and H-XS are joint first authors.  \nAccepted 30 March 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Xin-Rong Yang;  \n[yang.xinrong@zs-hospital.sh.cn](yang.xinrong@zs-hospital.sh.cn)  \nProfessor Zhong Chen; [chenz9806@163.com](chenz9806@163.com)  \nABSTRACT  \nBackground Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality worldwide. While immune checkpoint blockade has revolutionized the treatment of many cancers, responses in HCC remain limited. Robust functional platforms capable of predicting individual responses to immunotherapy are urgently needed. In this study, we developed a patient-derived organotypic tumor spheroid (PDOTS) model that preserves the heterogeneity and immune microenvironment of HCC, enabling rapid and reliable assessment of targeted and immunotherapeutic responses.  \nMethods Tumor tissues from 30 HCC patients were processed using a “Five-Point Clock” sampling method and cultured within a three-dimensional microfluidic chip supplemented with IL-2 and CD3/28 activator to maintain tumor-infiltrating lymphocyte activity. The genomic, immune, and histopathological fidelity of PDOTS relative to parental tumors was evaluated. Drug responses were assessed ex vivo and validated in matched patientderived xenograft (PDX) models. Transcriptomic profiling was subsequently performed to identify gene signatures associated with treatment sensitivity and to construct a transcriptomic predictive model.  \nResults The PDOTS retained ≥60% viability over 7 days and faithfully maintained the genomic, immune, and histopathological profiles of parental tumors. Functionally, PDOTS exhibited immune-dependent responses to PD-1 blockade and predicted treatment responses with 80% concordance in matched PDX models. Transcriptomic profiling revealed distinct metabolic and immune signatures in sensitive and resistant tumors, which were used to derive the “Organoid Killing Index (OKI)”. The OKI gene-derived index, a composite index integrating the enrichment scores of gene signatures associated with the OKI, strongly correlated (R=0 .829, p\u003C0 .001) and predicted clinical outcomes in an external patient cohort treated with atezolizumab plus bevacizumab.  \nConclusions These findings establish PDOTS as an immune-competent ex vivo platform for functional precision oncology and support the integration of  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Current biomarkers for immunotherapy in hepatocellular carcinoma (HCC) remain insufficient to reliably predict individual patient responses. Existing preclinical models, including conventional organoidsand patient-derived xenografts, either lack immune components or require prolonged establishment times, limiting their utility for rapid functional evaluation of immune checkpoint blockad","cbCailxd3Xa4Tigj","https://ap.wps.com/l/cbCailxd3Xa4Tigj","pdf",14438364,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# What this study adds\n## Current biomarker limitations\n## Study contributions\n## Potential research and policy impact","[{\"question\":\"What is the PDOTS model used for in this study?\",\"answer\":\"The study uses patient-derived organotypic tumor spheroids (PDOTS) as an ex vivo functional platform to assess immunotherapeutic responses while preserving the tumor–immune microenvironment.\"},{\"question\":\"How were PDOTS prepared and maintained for immune response testing?\",\"answer\":\"Tumor tissues from 30 HCC patients were processed with a “Five-Point Clock” sampling method and cultured in a three-dimensional microfluidic chip supplemented with IL-2 and CD3/28 activator to maintain tumor-infiltrating lymphocyte activity.\"},{\"question\":\"What predictive biomarker or model was derived from the PDOTS data?\",\"answer\":\"The work introduces the Organoid Killing Index (OKI) based on gene signatures from transcriptomic profiling, which correlated with and predicted clinical outcomes in an external cohort treated with atezolizumab plus bevacizumab.\"}]","Patient-derived organotypic tumor spheroids as a functional platform for predicting immunotherapeutic responses and guiding precision treatment for hepatocellular carcinoma - Original research | PDF",1790120383,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70c12eab0519d7ca239d4675afab7a98.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91cfb0830d64db17952390793ec87103.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8061839c8f1925416e4c231f12cdc37.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1bb872c0b660daf6f5beb255e32cd15e.webp",980,1306]